These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 27447854)

  • 1. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
    Radovich M; Kiel PJ; Nance SM; Niland EE; Parsley ME; Ferguson ME; Jiang G; Ammakkanavar NR; Einhorn LH; Cheng L; Nassiri M; Davidson DD; Rushing DA; Loehrer PJ; Pili R; Hanna N; Callaghan JT; Skaar TC; Helft PR; Shahda S; O'Neil BH; Schneider BP
    Oncotarget; 2016 Aug; 7(35):56491-56500. PubMed ID: 27447854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Community-driven development of a modified progression-free survival ratio for precision oncology.
    Mock A; Heilig CE; Kreutzfeldt S; Huebschmann D; Heining C; Schröck E; Brors B; Stenzinger A; Jäger D; Schlenk R; Glimm H; Fröhling S; Horak P;
    ESMO Open; 2019; 4(6):e000583. PubMed ID: 31798980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.
    Schwaederle M; Parker BA; Schwab RB; Daniels GA; Piccioni DE; Kesari S; Helsten TL; Bazhenova LA; Romero J; Fanta PT; Lippman SM; Kurzrock R
    Mol Cancer Ther; 2016 Apr; 15(4):743-52. PubMed ID: 26873727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive tumor profiling-guided therapy in rare or refractory solid cancer: A feasibility study in daily clinical practice.
    Ibrahim T; Ahmadie A; Rassy E; Karak FE; Hanna C; Farhat F; Kattan J; Ghosn M
    Bull Cancer; 2020 Apr; 107(4):410-416. PubMed ID: 32145962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.
    Bryce AH; Egan JB; Borad MJ; Stewart AK; Nowakowski GS; Chanan-Khan A; Patnaik MM; Ansell SM; Banck MS; Robinson SI; Mansfield AS; Klee EW; Oliver GR; McCormick JB; Huneke NE; Tagtow CM; Jenkins RB; Rumilla KM; Kerr SE; Kocher JA; Beck SA; Fernandez-Zapico ME; Farrugia G; Lazaridis KN; McWilliams RR
    Oncotarget; 2017 Apr; 8(16):27145-27154. PubMed ID: 28423702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
    Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
    Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative.
    Pishvaian MJ; Bender RJ; Halverson D; Rahib L; Hendifar AE; Mikhail S; Chung V; Picozzi VJ; Sohal D; Blais EM; Mason K; Lyons EE; Matrisian LM; Brody JR; Madhavan S; Petricoin EF
    Clin Cancer Res; 2018 Oct; 24(20):5018-5027. PubMed ID: 29954777
    [No Abstract]   [Full Text] [Related]  

  • 8. Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach.
    Kato S; Kurasaki K; Ikeda S; Kurzrock R
    Oncologist; 2018 Feb; 23(2):171-178. PubMed ID: 29038235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer.
    Cubillo A; Rodriguez-Pascual J; López-Ríos F; Plaza C; García E; Álvarez R; de Vicente E; Quijano Y; Hernando O; Rubio C; Perea S; Sanchez G; Hidalgo M
    Am J Clin Oncol; 2016 Jun; 39(3):236-42. PubMed ID: 24517959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis.
    Kim ST; Lee J; Hong M; Park K; Park JO; Ahn T; Park SH; Park YS; Lim HY; Sun JM; Ahn JS; Ahn MJ; Kim HC; Sohn TS; Choi DI; Cho JH; Heo JS; Kwon W; Uhm SW; Lee H; Min BH; Hong SN; Kim DH; Jung SH; Park W; Kim KM; Kang WK; Park K
    Oncotarget; 2015 Oct; 6(32):33358-68. PubMed ID: 26396172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference.
    Hall WA; Bergom C; Thompson RF; Baschnagel AM; Vijayakumar S; Willers H; Li XA; Schultz CJ; Wilson GD; West CML; Capala J; Coleman CN; Torres-Roca JF; Weidhaas J; Feng FY
    Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):274-284. PubMed ID: 28964588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision oncology based on omics data: The NCT Heidelberg experience.
    Horak P; Klink B; Heining C; Gröschel S; Hutter B; Fröhlich M; Uhrig S; Hübschmann D; Schlesner M; Eils R; Richter D; Pfütze K; Geörg C; Meißburger B; Wolf S; Schulz A; Penzel R; Herpel E; Kirchner M; Lier A; Endris V; Singer S; Schirmacher P; Weichert W; Stenzinger A; Schlenk RF; Schröck E; Brors B; von Kalle C; Glimm H; Fröhling S
    Int J Cancer; 2017 Sep; 141(5):877-886. PubMed ID: 28597939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
    Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
    Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining personalized treatment by gene expression profiling in metastatic breast carcinoma patients: a pilot study.
    Sureda M; Rebollo J; Martínez-Navarro EM; Fernández-Morejón FJ; Farré J; Muñoz V; Bretcha-Boix P; Duarte M; Manzano RG; Crespo A; Del Carmen Redal M; Valenzuela B; Brugarolas A
    Clin Transl Oncol; 2018 Jun; 20(6):785-793. PubMed ID: 29159791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
    Pierceall WE; Sprott KM; Heikkinen T; Heikkila P; Alaparthi L; Aittomaki K; Al-Adhami M; Villegas-Bergazzi V; Meyer JL; Kutok JL; Bartkova J; Bartek J; Nevanlinna H; Weaver DT; Blomqvist C
    Hum Pathol; 2012 Sep; 43(9):1363-75. PubMed ID: 22204715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
    Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physician interpretation of genomic test results and treatment selection.
    Brusco LL; Wathoo C; Mills Shaw KR; Holla VR; Bailey AM; Johnson AM; Khotskaya YB; Litzenburger BC; Sanchez NS; Zeng J; Bernstam EV; Eng C; Kee BK; Amaria RN; Routbort MJ; Mills GB; Mendelsohn J; Meric-Bernstam F
    Cancer; 2018 Mar; 124(5):966-972. PubMed ID: 29165790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Clinical Study of Precision Oncology in Solid Tumors.
    Sohal DP; Rini BI; Khorana AA; Dreicer R; Abraham J; Procop GW; Saunthararajah Y; Pennell NA; Stevenson JP; Pelley R; Estfan B; Shepard D; Funchain P; Elson P; Adelstein DJ; Bolwell BJ
    J Natl Cancer Inst; 2015 Nov; 108(3):. PubMed ID: 26553780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision oncology: East meets West.
    Subbiah V; Rodon J; Yap TA
    Int J Cancer; 2018 May; 142(9):1734-1737. PubMed ID: 29243227
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 27.